Literature DB >> 11152523

Rapid assessment of adenovirus serum neutralizing antibody titer based on quantitative, morphometric evaluation of capsid binding and intracellular trafficking: population analysis of adenovirus capsid association with cells is predictive of adenovirus infectivity.

T Vincent1, B G Harvey, S M Hogan, C J Bailey, R G Crystal, P L Leopold.   

Abstract

Neutralizing antiviral antibodies are typically detected on the basis of inhibition of viral function, such as propagation of a viral infection or inhibition of viral gene expression. Evidence is presented that anti-adenovirus neutralizing antibodies can be evaluated by analysis of cell-associated capsids or by analysis of intracellular trafficking of the capsids within 1 h after infection. Quantitative analyses of these morphologic parameters represent rapid, broadly applicable, functional assays for the detection of anti-adenovirus neutralizing antibodies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11152523      PMCID： PMC114056          DOI： 10.1128/JVI.75.3.1516-1521.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  20 in total

1.  Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells.

Authors:  P L Leopold; B Ferris; I Grinberg; S Worgall; N R Hackett; R G Crystal
Journal:  Hum Gene Ther       Date:  1998-02-10       Impact factor: 5.695

2.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Virus aggregation as the cause of the non-neutralizable persistent fraction.

Authors:  C Wallis; J L Melnick
Journal:  J Virol       Date:  1967-06       Impact factor: 5.103

4.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.

Authors:  Y Yang; Q Li; H C Ertl; J M Wilson
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo.

Authors:  M A Rosenfeld; W Siegfried; K Yoshimura; K Yoneyama; M Fukayama; L E Stier; P K Pääkkö; P Gilardi; L D Stratford-Perricaudet; M Perricaudet
Journal:  Science       Date:  1991-04-19       Impact factor: 47.728

6.  Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes.

Authors:  J Gall; A Kass-Eisler; L Leinwand; E Falck-Pedersen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

7.  "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.

Authors:  A Mastrangeli; B G Harvey; J Yao; G Wolff; I Kovesdi; R G Crystal; E Falck-Pedersen
Journal:  Hum Gene Ther       Date:  1996-01       Impact factor: 5.695

8.  Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector.

Authors:  J Hersh; R G Crystal; B Bewig
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

9.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Authors:  M A Rosenfeld; K Yoshimura; B C Trapnell; K Yoneyama; E R Rosenthal; W Dalemans; M Fukayama; J Bargon; L E Stier; L Stratford-Perricaudet
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

Review 10.  Neutralization of animal viruses.

Authors:  B Mandel
Journal:  Adv Virus Res       Date:  1978       Impact factor: 9.937
View more
  7 in total

1.  Cytoplasmic dynein mediates adenovirus binding to microtubules.

Authors:  Samir A Kelkar; K Kevin Pfister; Ronald G Crystal; Philip L Leopold
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Postentry neutralization of adenovirus type 5 by an antihexon antibody.

Authors:  Robin Varghese; Yeshi Mikyas; Phoebe L Stewart; Robert Ralston
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway.

Authors:  Philip L Leopold; Rebecca L Wendland; Theresa Vincent; Ronald G Crystal
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

5.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.

Authors:  Qiang Liu; Weijin Huang; Jianhui Nie; Rong Zhu; Dongying Gao; Aijing Song; Shufang Meng; Xuemei Xu; Youchun Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

7.  Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China.

Authors:  Qiang Liu; Jianhui Nie; Weijin Huang; Shufang Meng; Baozhu Yuan; Dongying Gao; Xuemei Xu; Youchun Wang
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.